TIDMSUPP

RNS Number : 2921F

Schroder UK Public Private Tst plc

04 November 2022

4 November 2022

Schroder UK Public Private Trust plc

Investment in iOnctura

Schroder UK Public Private Trust plc (the "Company") is pleased to announce it has made a EUR1.3 million (GBP1.1 million) investment in the clinical stage oncology company, iOnctura SA ("iOnctura"), as part of a convertible loan. All of the existing blue chip investor syndicate including M Ventures, INKEF Capital, VI Partners, and 3B Future Health participated in this financing.

iOnctura is a clinical-stage biotech with a portfolio of programs that each simultaneously target multiple core mechanisms involved in cancer resistance and survival. iOnctura's pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone. iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3K to treat Treg-driven tumours; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor to treat cancer associated fibroblast (CAF) driven tumours.

The Company is committed to improving its sustainability profile and intends to disclose, where appropriate, the United Nations' Sustainable Development Goals ("SDGs") associated with new investments. The investment in iOnctura is in line with SDG 3 "Good health and well-being", specifically Target 3.4 "Reduce mortality from non-communicable diseases and promote mental health" and Target 3.B "Support research, development and universal access to affordable vaccines and medicines".

Tim Creed and Roger Doig, Portfolio Managers of the Company, jointly commented: "iOnctura is the eleventh new investment and the third therapeutics focused private equity investment since our appointment as Portfolio Manager. This investment is in line with the Company's focus on backing innovative businesses with disruptive innovation, significant global growth potential, high quality management teams and supported by highly reputable co-investors".

Enquiries:

Schroder Investment Management Limited

 
 Augustine Chipungu (Press)     0207 658 2106 
 John Spedding                  0207 658 3206

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBKNBPKBDBQDK

(END) Dow Jones Newswires

November 04, 2022 03:00 ET (07:00 GMT)

Woodford Patient Capital (LSE:WPCT)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos Woodford Patient Capital.
Woodford Patient Capital (LSE:WPCT)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos Woodford Patient Capital.